<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://pmj.bmj.com">
<title>Postgraduate Medical Journal current issue</title>
<link>http://pmj.bmj.com</link>
<description>Postgraduate Medical Journal RSS feed -- current issue</description>
<prism:coverDisplayDate>Jun  1 2013 12:00:00:000AM</prism:coverDisplayDate>
<prism:publicationName>Postgraduate Medical Journal</prism:publicationName>
<prism:issn>0032-5473</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://pmj.bmj.com/cgi/content/short/89/1052/309?rss=1" />
  <rdf:li rdf:resource="http://pmj.bmj.com/cgi/content/short/89/1052/311?rss=1" />
  <rdf:li rdf:resource="http://pmj.bmj.com/cgi/content/short/89/1052/316?rss=1" />
  <rdf:li rdf:resource="http://pmj.bmj.com/cgi/content/short/89/1052/323?rss=1" />
  <rdf:li rdf:resource="http://pmj.bmj.com/cgi/content/short/89/1052/329?rss=1" />
  <rdf:li rdf:resource="http://pmj.bmj.com/cgi/content/short/89/1052/335?rss=1" />
  <rdf:li rdf:resource="http://pmj.bmj.com/cgi/content/short/89/1052/340?rss=1" />
  <rdf:li rdf:resource="http://pmj.bmj.com/cgi/content/short/89/1052/346?rss=1" />
  <rdf:li rdf:resource="http://pmj.bmj.com/cgi/content/short/89/1052/352?rss=1" />
  <rdf:li rdf:resource="http://pmj.bmj.com/cgi/content/short/89/1052/358?rss=1" />
  <rdf:li rdf:resource="http://pmj.bmj.com/cgi/content/short/89/1052/366?rss=1" />
  <rdf:li rdf:resource="http://pmj.bmj.com/cgi/content/short/89/1052/367?rss=1" />
  <rdf:li rdf:resource="http://pmj.bmj.com/cgi/content/short/89/1052/368?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://pmj.bmj.com/site/homepage/PMJ_95x60.gif" />
</channel>
<image rdf:about="http://pmj.bmj.com/site/homepage/PMJ_95x60.gif">
<title>Postgraduate Medical Journal</title>
<url>http://pmj.bmj.com/site/homepage/PMJ_95x60.gif</url>
<link>http://pmj.bmj.com</link>
</image>
<item rdf:about="http://pmj.bmj.com/cgi/content/short/89/1052/309?rss=1">
<title><![CDATA[Use of antiplatelet drugs in stroke prevention: time for a rethink?]]></title>
<link>http://pmj.bmj.com/cgi/content/short/89/1052/309?rss=1</link>
<description><![CDATA[ <p>Worldwide, 15 million people suffer stroke each year from which a third die and a further third sustain severe disability, with ischaemic events accounting for ~80% of all strokes.<cross-ref type="bib" refid="R1">1</cross-ref> The annual estimated economic burden of stroke is 64.1 billion in Europe alone.<cross-ref type="bib" refid="R2">2</cross-ref> While recent major investments in acute stroke services have focused on thrombolysis and hospitalisation in dedicated stroke wards, we believe that primary and secondary stroke prevention should remain of utmost importance in a disease that carries such serious permanent neurological sequelae. Antiplatelet agents such as aspirin, diypridamole or clodpidogrel are pharmacological options that can have a potentially beneficial role in stroke prevention, but healthcare professionals should also take account of several major limitations in the use of these drugs.</p> <p>One of the major challenges in primary prevention of stroke stems from the need to accurately identify the at-risk group from seemingly healthy participants....]]></description>
<dc:creator><![CDATA[Loke, Y. K., White, J. R., Bettencourt-Silva, J. H., Potter, J. F., Myint, P. K.]]></dc:creator>
<dc:date>2013-05-17T01:04:30-07:00</dc:date>
<dc:identifier>info:doi/10.1136/postgradmedj-2012-131446</dc:identifier>
<dc:identifier>hwp:master-id:postgradmedj;postgradmedj-2012-131446</dc:identifier>
<dc:publisher>The Fellowship of Postgraduate Medicine</dc:publisher>
<dc:subject><![CDATA[GI bleeding, Drugs: cardiovascular system, Stroke, Ischaemic heart disease, Epidemiology]]></dc:subject>
<dc:title><![CDATA[Use of antiplatelet drugs in stroke prevention: time for a rethink?]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Editorials</prism:section>
<prism:volume>89</prism:volume>
<prism:number>1052</prism:number>
<prism:startingPage>309</prism:startingPage>
<prism:endingPage>310</prism:endingPage>
</item>
<item rdf:about="http://pmj.bmj.com/cgi/content/short/89/1052/311?rss=1">
<title><![CDATA[Medical students' subjective ratings of stress levels and awareness of student support services about mental health]]></title>
<link>http://pmj.bmj.com/cgi/content/short/89/1052/311?rss=1</link>
<description><![CDATA[
<sec><st>Purpose</st>
<p>To descriptively assess medical students&rsquo; concerns for their mental and emotional state, perceived need to conceal mental problems, perceived level of support at university, knowledge and use of student support services, and experience of stresses of daily life.</p>
</sec>
<sec><st>Study design</st>
<p>From March to September 2011, medical students at an Australian university were invited to complete an anonymous online survey.</p>
</sec>
<sec><st>Results</st>
<p>475 responses were received. Students rated study and examinations (48.9%), financial concerns (38.1%), isolation (19.4%) and relationship concerns (19.2%) as very or extremely stressful issues. Knowledge of available support services was high, with 90.8% indicating they were aware of the university's medical centre. Treatment rates were modest (31.7%). Students&rsquo; concerns about their mental state were generally low, but one in five strongly felt they needed to conceal their emotional problems.</p>
</sec>
<sec><st>Conclusions</st>
<p>Despite widespread awareness of appropriate support services, a large proportion of students felt they needed to conceal mental and emotional problems. Overall treatment rates for students who were greatly concerned about their mental and emotional state appeared modest, and, although comparable with those of similarly aged community populations, may reflect undertreatment. It would be appropriate for universities to address stressors identified by students. Strategies for encouraging distressed students to obtain appropriate assessment and treatment should also be explored. Those students who do seek healthcare are most likely to see a primary care physician, suggesting an important screening role for these health professionals.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Walter, G., Soh, N. L.-W., Norgren Jaconelli, S., Lampe, L., Malhi, G. S., Hunt, G.]]></dc:creator>
<dc:date>2013-05-17T01:04:30-07:00</dc:date>
<dc:identifier>info:doi/10.1136/postgradmedj-2012-131343</dc:identifier>
<dc:identifier>hwp:master-id:postgradmedj;postgradmedj-2012-131343</dc:identifier>
<dc:publisher>The Fellowship of Postgraduate Medicine</dc:publisher>
<dc:subject><![CDATA[General practice / family medicine, Epidemiology]]></dc:subject>
<dc:title><![CDATA[Medical students' subjective ratings of stress levels and awareness of student support services about mental health]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Original article</prism:section>
<prism:volume>89</prism:volume>
<prism:number>1052</prism:number>
<prism:startingPage>311</prism:startingPage>
<prism:endingPage>315</prism:endingPage>
</item>
<item rdf:about="http://pmj.bmj.com/cgi/content/short/89/1052/316?rss=1">
<title><![CDATA[Variation in cost of newly qualified doctors' prescriptions: a review of data from a hospital electronic prescribing system]]></title>
<link>http://pmj.bmj.com/cgi/content/short/89/1052/316?rss=1</link>
<description><![CDATA[
<sec><st>Purpose of the study</st>
<p>To investigate the variation in the net ingredient cost (NIC) of the medications most commonly prescribed by Foundation Year 1 (F1) doctors in a teaching hospital and to compare the effects of working in different specialties and rotations on this cost.</p>
</sec>
<sec><st>Design of the study</st>
<p>Retrospective review of prescription data from 5 August 2010 to 3 August 2011 extracted from an electronic prescribing system.</p>
</sec>
<sec><st>Results</st>
<p>The F1 doctors generated 81&nbsp;316 prescriptions with an estimated total cost of &pound;579&nbsp;398. The mean NIC per doctor was &pound;7334 (SE=&pound;430). Prescribing costs varied significantly across clinical departments and between drug classes considered in the analysis. Specifically, prescribing in the infection and respiratory drug categories and within the trauma and orthopaedics department was associated with higher prescribing costs. Significant variability was also attributable to the prescribing doctor (p&lt;0.001) with average prescription costs ranging from 72.2% lower to 193.8% higher than the median doctor.</p>
</sec>
<sec><st>Conclusions</st>
<p>There is considerable variation in the total costs of medications prescribed by F1 doctors, even after considering a range of prescription factors. This variation may suggest that some doctors are prescribing uneconomically relative to the rest of the cohort. Knowledge of which clinical areas and drug classes have higher NICs may allow an alternative focus for medicine management teams and postgraduate education.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Nwulu, U., Hodson, J., Thomas, S. K., Westwood, D., Griffin, C., Coleman, J. J.]]></dc:creator>
<dc:date>2013-05-17T01:04:30-07:00</dc:date>
<dc:identifier>info:doi/10.1136/postgradmedj-2012-131334</dc:identifier>
<dc:identifier>hwp:master-id:postgradmedj;postgradmedj-2012-131334</dc:identifier>
<dc:publisher>The Fellowship of Postgraduate Medicine</dc:publisher>
<dc:title><![CDATA[Variation in cost of newly qualified doctors' prescriptions: a review of data from a hospital electronic prescribing system]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Original article</prism:section>
<prism:volume>89</prism:volume>
<prism:number>1052</prism:number>
<prism:startingPage>316</prism:startingPage>
<prism:endingPage>322</prism:endingPage>
</item>
<item rdf:about="http://pmj.bmj.com/cgi/content/short/89/1052/323?rss=1">
<title><![CDATA[Deep brain stimulation: a return journey from psychiatry to neurology]]></title>
<link>http://pmj.bmj.com/cgi/content/short/89/1052/323?rss=1</link>
<description><![CDATA[
<p>Deep brain stimulation (DBS) has emerged as an effective neurosurgical tool to treat a range of conditions. Its use in movement disorders such as Parkinson's disease, tremor and dystonia is now well established and has been approved by the National Institute of Clinical Excellence (NICE). The NICE does, however, emphasise the need for a multidisciplinary team to manage these patients. Such a team is traditionally composed of neurologists, neurosurgeons and neuropsychologists. Neuropsychiatrists, however, are increasingly recognised as essential members given many psychiatric considerations that may arise in patients undergoing DBS. Patient selection, assessment of competence to consent and treatment of postoperative psychiatric disease are just a few areas where neuropsychiatric input is invaluable. Partly driven by this close team working and partly based on the early history of DBS for psychiatric disorders, there is increasing interest in re-exploring the potential of neurosurgery to treat patients with psychiatric disease, such as depression and obsessive&ndash;compulsive disorder. Although the clinical experience and evidence with DBS in this group of patients are steadily increasing, many questions remain unanswered. Yet, the characteristics of optimal surgical candidates, the best choice of DBS target, the most effective stimulating parameters and the extent of postoperative improvement are not clear for most psychiatric conditions. Further research is therefore required to define how DBS can be best utilised to improve the quality of life of patients with psychiatric disease.</p>
]]></description>
<dc:creator><![CDATA[Ashkan, K., Shotbolt, P., David, A. S., Samuel, M.]]></dc:creator>
<dc:date>2013-05-17T01:04:30-07:00</dc:date>
<dc:identifier>info:doi/10.1136/postgradmedj-2012-131520</dc:identifier>
<dc:identifier>hwp:master-id:postgradmedj;postgradmedj-2012-131520</dc:identifier>
<dc:publisher>The Fellowship of Postgraduate Medicine</dc:publisher>
<dc:subject><![CDATA[Editor's choice, Drugs: CNS (not psychiatric), Parkinson's disease, Anxiety disorders (including OCD and PTSD)]]></dc:subject>
<dc:title><![CDATA[Deep brain stimulation: a return journey from psychiatry to neurology]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Original article</prism:section>
<prism:volume>89</prism:volume>
<prism:number>1052</prism:number>
<prism:startingPage>323</prism:startingPage>
<prism:endingPage>328</prism:endingPage>
</item>
<item rdf:about="http://pmj.bmj.com/cgi/content/short/89/1052/329?rss=1">
<title><![CDATA[Outcomes in UK patients with hospital-acquired bacteraemia and the risk of catheter-associated urinary tract infections]]></title>
<link>http://pmj.bmj.com/cgi/content/short/89/1052/329?rss=1</link>
<description><![CDATA[
<sec><st>Purpose</st>
<p>There is lack of contemporary outcome data on patients with hospital-acquired infections that cause bacteraemia. We determined the risk factors for 7-day mortality and investigated the hypothesis that, compared with central venous catheter (CVC)-associated bacteraemic infections, catheter-associated bacteraemic urinary tract infections (UTIs) were significantly associated with 7-day mortality.</p>
</sec>
<sec><st>Methods</st>
<p>From October 2007 to September 2008, demographical, clinical and microbiological data were collected on patients with hospital-acquired bacteraemia. Patients were followed until death, hospital discharge or recovery from infection. Risk factors for 7-day mortality were determined and multivariate logistic regression was used to define the association between catheter-associated bacteraemic UTIs and likelihood of death.</p>
</sec>
<sec><st>Results</st>
<p>559 bacteraemic episodes occurred in 437 patients. Overall, there were 90 deaths (20.6%) at 7&nbsp;days and 153 deaths (35.0%) at 30&nbsp;days. Among patients with catheter-associated bacteraemic UTIs, 7-day and 30-day mortalities associated with each bacteraemic episode were 25/83 (30.1%) and 33/83 (39.8%), respectively. Within this subgroup, the commonest isolates were <I>Escherichia coli</I>, 36 (43.4%), <I>Proteus mirabilis</I>, 11 (13.3%) and <I>Pseudomonas aeruginosa</I>, 9 (10.8%). There were 22 (26.5%) multiple drug-resistant isolates and, of the <I>E coli</I> infections, 6 (16.7%) were extended spectrum &beta;-lactamase producers. In univariate analysis, the variables found to have the strongest association with 7-day mortality were age, Pitt score, Charlson comorbidity index (CCI), medical speciality and site of infection. Compared with CVC-associated bacteraemic infections, there was a significant association between catheter-associated bacteraemic UTIs and 7-day mortality (OR 4.16, 95% CI 1.86 to 9.33). After adjustment for age and CCI, this association remained significant (OR 2.90, 95% CI 1.19 to 7.07).</p>
</sec>
<sec><st>Conclusions</st>
<p>Compared with CVC-associated bacteraemic infections, catheter-associated bacteraemic UTIs were significantly associated with 7-day mortality. Efforts to reduce these infections should be prioritised.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Melzer, M., Welch, C.]]></dc:creator>
<dc:date>2013-05-17T01:04:30-07:00</dc:date>
<dc:identifier>info:doi/10.1136/postgradmedj-2012-131393</dc:identifier>
<dc:identifier>hwp:master-id:postgradmedj;postgradmedj-2012-131393</dc:identifier>
<dc:publisher>The Fellowship of Postgraduate Medicine</dc:publisher>
<dc:subject><![CDATA[Urology, Open access, Drugs: infectious diseases, Epidemiology]]></dc:subject>
<dc:title><![CDATA[Outcomes in UK patients with hospital-acquired bacteraemia and the risk of catheter-associated urinary tract infections]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Original article</prism:section>
<prism:volume>89</prism:volume>
<prism:number>1052</prism:number>
<prism:startingPage>329</prism:startingPage>
<prism:endingPage>334</prism:endingPage>
</item>
<item rdf:about="http://pmj.bmj.com/cgi/content/short/89/1052/335?rss=1">
<title><![CDATA[Failure to improve door-to-needle time by switching to emergency physician-initiated thrombolysis for ST elevation myocardial infarction]]></title>
<link>http://pmj.bmj.com/cgi/content/short/89/1052/335?rss=1</link>
<description><![CDATA[
<sec><st>Introduction</st>
<p>Achieving target door&ndash;needle times for ST elevation myocardial infarction remains challenging. Data on emergency department (ED) doctor-led thrombolysis in developing countries and factors causing delay are limited.</p>
</sec>
<sec><st>Objectives</st>
<p>To assess the effect on door&ndash;needle times by transferring responsibility for thrombolysis to the ED doctors and to identify predictors of prolonged door&ndash;needle times.</p>
</sec>
<sec><st>Methodology</st>
<p>Data on medical on-call team-led thrombolysis at a tertiary Asian hospital were prospectively collected from May 2007 to Aug 2008 (1st study period). In September 2008, ED doctors were empowered to perform thrombolysis. The practice change was accompanied by new guidelines, tick chart implementation, and training sessions. Data were then consecutively collected from September 2008 to May 2009 (2nd study period). Door-to-needle times for the 1st and 2nd study periods were compared. All cases were analysed for factors of delay by multiple logistic regression.</p>
</sec>
<sec><st>Results</st>
<p>297 patients were thrombolysed, 169 by the medical on-call team during the 1st study period and 128 by the ED doctors during the 2nd study period. Median door&ndash;needle times were 54 and 48&nbsp;min, respectively (p=0.76). Significant delays were predicted by &lsquo;incorrect initial ECG interpretation&rsquo; (adjusted OR (aOR) 14.3), &lsquo;inappropriate triage&rsquo; (aOR 10.4) and &lsquo;multiple referrals&rsquo; (aOR 5.9). No cases of inappropriate thrombolysis were recorded.</p>
</sec>
<sec><st>Conclusions</st>
<p>Transfer of responsibility for thrombolysis to the ED doctors did not improve door&ndash;needle times despite measures introduced to facilitate this change. Key causative factors for this failure were identified.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Loch, A., Lwin, T., Zakaria, I. M., Abidin, I. Z., Wan Ahmad, W. A., Hautmann, O.]]></dc:creator>
<dc:date>2013-05-17T01:04:30-07:00</dc:date>
<dc:identifier>info:doi/10.1136/postgradmedj-2012-131174</dc:identifier>
<dc:identifier>hwp:master-id:postgradmedj;postgradmedj-2012-131174</dc:identifier>
<dc:publisher>The Fellowship of Postgraduate Medicine</dc:publisher>
<dc:subject><![CDATA[Emergency medicine, Open access, Drugs: cardiovascular system, Ischaemic heart disease, Radiology, Clinical diagnostic tests]]></dc:subject>
<dc:title><![CDATA[Failure to improve door-to-needle time by switching to emergency physician-initiated thrombolysis for ST elevation myocardial infarction]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Original article</prism:section>
<prism:volume>89</prism:volume>
<prism:number>1052</prism:number>
<prism:startingPage>335</prism:startingPage>
<prism:endingPage>339</prism:endingPage>
</item>
<item rdf:about="http://pmj.bmj.com/cgi/content/short/89/1052/340?rss=1">
<title><![CDATA[Meningococcal sepsis and purpura fulminans: the surgical perspective]]></title>
<link>http://pmj.bmj.com/cgi/content/short/89/1052/340?rss=1</link>
<description><![CDATA[
<p>Meningococcal sepsis and purpura fulminans is a rare but highly lethal disease process that requires a multidisciplinary team of experts to optimise morbidity and mortality outcomes due to the breadth of complications of the disease. The surgical perspective involves the critical care management which utilises all currently available measured outcomes of critical care management as well as experimental therapies. Limb loss is common, and is reflective of the high incidence of compartment syndrome compounded by the significant soft tissue loss secondary to purpura and limb ischaemia, presumptively due to digital microemboli. A multidisciplinary approach involving current standards in critical care and early surgical evaluation are important in improving patient outcomes and limb salvage.</p>
]]></description>
<dc:creator><![CDATA[Morris, M. E., Maijub, J. G., Walker, S. K., Gardner, G. P., Jones, R. G.]]></dc:creator>
<dc:date>2013-05-17T01:04:30-07:00</dc:date>
<dc:identifier>info:doi/10.1136/postgradmedj-2012-130989</dc:identifier>
<dc:identifier>hwp:master-id:postgradmedj;postgradmedj-2012-130989</dc:identifier>
<dc:publisher>The Fellowship of Postgraduate Medicine</dc:publisher>
<dc:title><![CDATA[Meningococcal sepsis and purpura fulminans: the surgical perspective]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Reviews</prism:section>
<prism:volume>89</prism:volume>
<prism:number>1052</prism:number>
<prism:startingPage>340</prism:startingPage>
<prism:endingPage>345</prism:endingPage>
</item>
<item rdf:about="http://pmj.bmj.com/cgi/content/short/89/1052/346?rss=1">
<title><![CDATA[Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice]]></title>
<link>http://pmj.bmj.com/cgi/content/short/89/1052/346?rss=1</link>
<description><![CDATA[
<p>Atrial fibrillation, the commonest cardiac arrhythmia, predisposes to thrombus formation and consequently increases risk of ischaemic stroke. Recent years have seen approval of a number of novel oral anticoagulants. Nevertheless, warfarin and aspirin remain the mainstays of therapy. It is widely appreciated that both these agents increase the likelihood of bleeding: there is a popular conception that this risk is greater with warfarin. In fact, well-managed warfarin therapy (INR 2-3) has little effect on bleeding risk and is twice as effective as aspirin at preventing stroke. Patients with atrial fibrillation and a further risk factor for stroke (CHA2DS2-VASc &gt;0) should therefore either receive warfarin or a novel oral agent. The remainder who are at the very lowest risk of stroke are better not prescribed antithrombotic therapy. For stroke prevention in atrial fibrillation; aspirin is rarely the right choice.</p>
]]></description>
<dc:creator><![CDATA[Sabir, I. N., Matthews, G. D. K., Huang, C. L.-H.]]></dc:creator>
<dc:date>2013-05-17T01:04:30-07:00</dc:date>
<dc:identifier>info:doi/10.1136/postgradmedj-2012-131386</dc:identifier>
<dc:identifier>hwp:master-id:postgradmedj;postgradmedj-2012-131386</dc:identifier>
<dc:publisher>The Fellowship of Postgraduate Medicine</dc:publisher>
<dc:subject><![CDATA[Open access]]></dc:subject>
<dc:title><![CDATA[Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Reviews</prism:section>
<prism:volume>89</prism:volume>
<prism:number>1052</prism:number>
<prism:startingPage>346</prism:startingPage>
<prism:endingPage>351</prism:endingPage>
</item>
<item rdf:about="http://pmj.bmj.com/cgi/content/short/89/1052/352?rss=1">
<title><![CDATA[Republished: Non-invasive urine based tests for the detection of bladder cancer]]></title>
<link>http://pmj.bmj.com/cgi/content/short/89/1052/352?rss=1</link>
<description><![CDATA[
<p>Bladder cancer is the fourth most frequently diagnosed malignant neoplasm and cause of cancer-related deaths in men and eighth in women. Patients with bladder cancer undergo repeated cystoscopic examinations of the bladder to monitor for tumour recurrence which is invasive, costly and lacks accuracy. Therefore, the development of non-invasive urine based tests for the early detection of bladder cancer would be of tremendous benefit to both patients and healthcare systems. A number of urine based markers are available for the early diagnosis of bladder cancer. The diagnosis of bladder cancer relies on identifying malignant cells in the urine. All urinary markers have a higher sensitivity as compared with cytology but they score lower in specificity. Many soluble and cell based markers have been developed. Only two of the soluble and cell based markers have obtained the Food and Drug Administration approval. In the current review, the most recent literature of urinary markers is summarised. This article reports some of the more prominent urine markers and new technologies used nowadays.</p>
]]></description>
<dc:creator><![CDATA[Wadhwa, N., Jatawa, S. K., Tiwari, A.]]></dc:creator>
<dc:date>2013-05-17T01:04:30-07:00</dc:date>
<dc:identifier>info:doi/10.1136/postgradmedj-2012-200812rep</dc:identifier>
<dc:identifier>hwp:master-id:postgradmedj;postgradmedj-2012-200812rep</dc:identifier>
<dc:publisher>The Fellowship of Postgraduate Medicine</dc:publisher>
<dc:subject><![CDATA[Urology, Urological cancer, Screening (oncology)]]></dc:subject>
<dc:title><![CDATA[Republished: Non-invasive urine based tests for the detection of bladder cancer]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Republished review</prism:section>
<prism:volume>89</prism:volume>
<prism:number>1052</prism:number>
<prism:startingPage>352</prism:startingPage>
<prism:endingPage>357</prism:endingPage>
</item>
<item rdf:about="http://pmj.bmj.com/cgi/content/short/89/1052/358?rss=1">
<title><![CDATA[Republished: Paediatric early warning scores: Holy Grail and Achilles' heel]]></title>
<link>http://pmj.bmj.com/cgi/content/short/89/1052/358?rss=1</link>
<description><![CDATA[
<p>Early Warning Scores (EWS) have become increasingly used by hospitals throughout the world to prevent unexpected admission to intensive care or even death in their inpatient population. It is well known that signs of deterioration are present well before collapse and by a combination of systems, EWS enable healthcare professionals to intervene at an appropriate time. A number of national bodies and regulators in the UK have required the use of Early Warning Scores in locations where children are inpatients. This article attempts to describe the background to their development, identify common problems and provide information for units interested in introducing an EWS into their department.</p>
]]></description>
<dc:creator><![CDATA[Roland, D.]]></dc:creator>
<dc:date>2013-05-17T01:04:30-07:00</dc:date>
<dc:identifier>info:doi/10.1136/postgradmedj-2011-300976rep</dc:identifier>
<dc:identifier>hwp:master-id:postgradmedj;postgradmedj-2011-300976rep</dc:identifier>
<dc:publisher>The Fellowship of Postgraduate Medicine</dc:publisher>
<dc:subject><![CDATA[Adult intensive care]]></dc:subject>
<dc:title><![CDATA[Republished: Paediatric early warning scores: Holy Grail and Achilles' heel]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Republished best practice</prism:section>
<prism:volume>89</prism:volume>
<prism:number>1052</prism:number>
<prism:startingPage>358</prism:startingPage>
<prism:endingPage>365</prism:endingPage>
</item>
<item rdf:about="http://pmj.bmj.com/cgi/content/short/89/1052/366?rss=1">
<title><![CDATA[Abdominal trauma and lung nodules]]></title>
<link>http://pmj.bmj.com/cgi/content/short/89/1052/366?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Introduction</st> <p>Splenosis represents the deposition of viable splenic tissue in a different anatomic compartment, usually following trauma. The extent of deposition is related to the severity of trauma and amount of pulp tissue released into the abdominal and pelvic cavities. Thoracic splenosis, is the deposition of splenic tissue within the thoracic cavity and occurs in about 18% of cases.<cross-ref type="bib" refid="R1">1</cross-ref> This splenic tissue is thought to perform normal splenic functions and draws its blood supply from surrounding tissue. The condition is usually discovered incidentally, and patients are often asymptomatic males as in the case described below.</p> </sec> <sec id="s2"><st>Case</st> <p>A 42-year-old male smoker presented with abdominal pain. A CT abdomen and chest showed calcified pleural thickening, old left rib fractures, and several lung nodules (majority pleural, positron emission tomography negative) (<cross-ref type="fig" refid="POSTGRADMEDJ2012131359F1">figure 1</cross-ref>) in the left hemithorax. He was referred to the chest clinic with suspected...]]></description>
<dc:creator><![CDATA[Nazareth, D., Seshadri, N., Binukrishnan, S., Ledson, M., Walshaw, M., Mohan, K.]]></dc:creator>
<dc:date>2013-05-17T01:04:30-07:00</dc:date>
<dc:identifier>info:doi/10.1136/postgradmedj-2012-131359</dc:identifier>
<dc:identifier>hwp:master-id:postgradmedj;postgradmedj-2012-131359</dc:identifier>
<dc:publisher>The Fellowship of Postgraduate Medicine</dc:publisher>
<dc:subject><![CDATA[Journalology, Immunology (including allergy), Pain (neurology), Lung cancer (oncology), Screening (oncology), Radiology, Lung cancer (respiratory medicine), Clinical diagnostic tests, Radiology (diagnostics), Ethics]]></dc:subject>
<dc:title><![CDATA[Abdominal trauma and lung nodules]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Images in medicine</prism:section>
<prism:volume>89</prism:volume>
<prism:number>1052</prism:number>
<prism:startingPage>366</prism:startingPage>
<prism:endingPage>366</prism:endingPage>
</item>
<item rdf:about="http://pmj.bmj.com/cgi/content/short/89/1052/367?rss=1">
<title><![CDATA[Meet your microbiome]]></title>
<link>http://pmj.bmj.com/cgi/content/short/89/1052/367?rss=1</link>
<description><![CDATA[ <p>Last year I had the privilege of meeting Elling Ulvestad, a Norwegian microbiologist who is also a philosopher. He is a man of enormous warmth and energy, as well as having inexhaustible enthusiasm for his subject. He can soon convince anybody that the world is in great need of a philosophy that is properly informed by microbiology, and vice versa. Here are the kinds of facts that Professor Ulvestad has on the tip of his tongue. We carry 10 times as many bacterial cells around on our bodies as we do of our own cells (the disproportion is because microbes are very much smaller than mammalian cells). If you also count the bacteriophages that inhabit bacteria, the ratio of micro-organisms to human cells on each of us is probably more like 1000 : 1. Although we commonly regard bacteria as enemies, only around 100 species regularly infect human beings, while literally...]]></description>
<dc:creator><![CDATA[Launer, J.]]></dc:creator>
<dc:date>2013-05-17T01:04:30-07:00</dc:date>
<dc:identifier>info:doi/10.1136/postgradmedj-2013-132066</dc:identifier>
<dc:identifier>hwp:master-id:postgradmedj;postgradmedj-2013-132066</dc:identifier>
<dc:publisher>The Fellowship of Postgraduate Medicine</dc:publisher>
<dc:title><![CDATA[Meet your microbiome]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>On reflection</prism:section>
<prism:volume>89</prism:volume>
<prism:number>1052</prism:number>
<prism:startingPage>367</prism:startingPage>
<prism:endingPage>368</prism:endingPage>
</item>
<item rdf:about="http://pmj.bmj.com/cgi/content/short/89/1052/368?rss=1">
<title><![CDATA[Correction]]></title>
<link>http://pmj.bmj.com/cgi/content/short/89/1052/368?rss=1</link>
<description><![CDATA[
<sec id="s1">
<p>Pinto A, Faiz O, Vincent C. Republished: Managing the after effects of serious patient safety incidents in the NHS: an online survey study. <I>Postgrad Med J</I> 2013;<b>89</b>:266&ndash;273.</p>
<p>In the abstract, under Results, the sentence "two-thirds of the discussions taking place 3&ndash;6 weeks after the investigation" should read "two-thirds of the discussions taking place 3&ndash;6 months after the investigation". Also in the main text, under the results, the sentence "two-thirds take place 3&ndash;6 weeks after the investigation" should read "two-thirds take place 3&ndash;6 months after the investigation".</p>
</sec>
]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2013-05-17T01:04:30-07:00</dc:date>
<dc:identifier>info:doi/10.1136/postgradmedj-2012-000826rep.corr1</dc:identifier>
<dc:identifier>hwp:master-id:postgradmedj;postgradmedj-2012-000826rep.corr1</dc:identifier>
<dc:publisher>The Fellowship of Postgraduate Medicine</dc:publisher>
<dc:title><![CDATA[Correction]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Correction</prism:section>
<prism:volume>89</prism:volume>
<prism:number>1052</prism:number>
<prism:startingPage>368</prism:startingPage>
<prism:endingPage>368</prism:endingPage>
</item>
</rdf:RDF>